Preliminary clinical experience of the systemic use of 153Sm-EDTMP as a pain palliation agent in arthrosis and as an option for bone scanning in patients with bone metastases

Abstract

Introduction: Many patients with arthrosis have side effects produced by conventional treatments. These patients are candidates for pain palliation with 153Sm-EDTMP. Patients with cancer bone metastases usuaLly require a bone scanning procedure using ““Tc-MDP, prior to treatment through 153Sm-EDTMP. This work has two aims. Firstly, to assess the use of 153Sm- EDTMP as an alternative in bone scanning procedures in patients with bones metastases. Se condly, if the 153Sm-EDTMP is uptaken by the arthrosis injured joint, then the efficient and safe use of the systemic administration of this radiopharmaceutical is evaluated for pain palliation. Methods and materials: A non-probabilistic, of opportunity and sequential sample of 10 patients with arthrosis was selected, as well as, one patient with bone metastasis secondary to prostate cancer. In the li patients, bone scans were performed using both radiopharmaceuticals “‘T1Tc- MDP and 153Sm-EDTMP to compare image quality and uptake sites. In patients with arthrosis a therapeutic dose with ‘53Sm-EDTMP was systemically administered for pain palliation. Hemato logic profiles were performed in order to assure security to the bone marrow. Pain and motility evaluations were carried out to assess the Sm-EDTMP analgesic efficacy. Results and conclusion: The Image qualities obtained with 13Sm-EDTMP are similar from the cLinical point of view to those obtained with ““Tc-MDR Sm-EDTMP is captured by joints with arthrosis and bone metastases. Therapeutic doses of 1Sm-EDTMP intravenously administered are well tolerated by the bone marrow, while an analgesic effect is present which improves motility and quality of Life in patients with arthrosis.